Navigate Up
Sign In

Professional Programs

The Professional Programs Subcommittee is responsible for organizing and planning in-person programs at stated meetings, webinars, and the like of potential interest to the membership of the Chemical Practice Committee.  

If you are interested in getting involved with the Professional Programs Subcommittee or provide any suggestions for future programs, webinars and the like of potential interest to this committee, please reach out to Drew Patty via email at

Professional Programs Subcommittee Chairs
McGlinchey Stafford

Robert Titus
Eli Lilly and Company​

Please see below upcoming and past professional programs for the Chemical Practice Committee:

2018 AIPLA Annual Meeting, Washington D.C.
Friday, October 26, 2018 from 3:30 - 5:30 PM

Chemical Practice, Emerging Technologies and Electronics and Computer Law Committees Joint CLE Educational Session

Powering Our Future with the Future of Power: Emerging Trends in Charging Technologies

This session will address electrical energy storage technologies and related intellectual property legal issues. We hope you’re as energized about this topic as we are. It should be an electrifyingly good time. ​

2018 AIPLA Spring Meeting, Westin Seattle, Seattle Washington
Wednesday, May 16, 2018 from 3:30 - 5:30 PM

Chemical Practice / Patent Agents Committees Joint CLE Educational Session

Welcome to The Machine: The Impact of The Application of Computational Techniques and Artificial Intelligence to The Chemical Arts

Panelists discussed the current state of the computational chemistry, virtual research and simulated biological systems and the challenges of AI inventions on the patent system.  What is the invention? When does it occur? Who owns it?  They engaged in an interactive discussion with the audience regarding the relationship between patent eligibility, predictability, and obviousness, enablement and written description for these types of inventions.  ​

Moderator: Angela Sebor, Ph.D., Tolmar, Inc., Fort Collins, CO

Part I: The Current State of the Technical Art of Computational Chemistry, Virtual Reactors and Simulated Biological Systems

Speaker:​ Martha S. Head (Marti), Ph.D., Director, Joint Institute of Biological Sciences, Oak Ridge National Laboratory, Oak Ridge, TN

Marti Head is director of the Joint Institute for Biological Sciences, a collaborative research effort between Oak Ridge National Laboratory and the University of Tennessee focused on new approaches to drug development, personalized treatment, diagnosis and prediction of outcomes in health management.  Previous to her role at Oak Ridge, Marti was for twenty years a computational scientist at GlaxoSmithKline Pharmaceuticals (GSK), where she was senior director of the The Noldor, a collaborative GSK-Palantir team, and head of the Insights from Data team in the Platform Technology and Sciences (PTS) department of GSK. PTS spans the entire range of drug discovery and development, partnering with the therapeutic areas from initial biological hypothesis through selection of clinical candidate and formulation of physical drug product.  From 2007 to 2014, Marti was the director of Computational Chemistry US at GSK, a 30-person, cross-site team responsible for proactively and creatively applying computational technologies to drive programs across all of GSK’s therapeutic areas from target selection through to candidate selection. 

Part II: Invention and Inventorship Using AI:  What is the “Invention,” When Does It Occur, and Who Owns It?

Speaker: Susan Y. Tull, Esq.Finnegan Henderson, Washington, D.C.

​​​Susan Tull has been involved in all phases and forums of litigation. Her patent litigation, appeals, and post-grant proceedings practices focus on technologies related to consumer products, software, AI, medical devices, automotive, and other mechanical and electrical systems. Susan focuses her practice on patent litigation and client counseling in the mechanical, computer science, electrical, and medical device fields.  Susan has researched and written extensively on patenting artificial intelligence and software as a medical device.

Part III: AI and Patentability - Understanding the Relationship Between Patent Eligibility, Predictability vs. Obviousness, Enablement and Written Description in the Chemical Arts

Speaker: Brian Roberts-Stanton, Ph.D.​Stanton Consulting Services, LLC, Alachua FL

Brian Stanton is an independent intellectual property (IP) consultant.  He works on IP, trade, and associated technology innovation policy matters. Dr. Stanton’s principle activities include strategic IP analysis and federal regulatory affairs consulting.  He was the Director of the Division of Policy at the National Institutes of Health’s (NIH), Office of Technology Transfer until 2007.  Prior to that, he was posted at the US Patent and Trademark Office (USPTO) and co-led efforts in establishing IP standards for biotechnology and pharmaceutical patenting. Dr. Stanton’s accomplishments include establishing global “best-practices” for licensing of DNA based invention, fostering public/private partnerships in drug discovery with the World Health Organization and Health Canada, establishing global technology transfer pathways to facilitate vaccine delivery to developing countries. Dr. Stanton was also instrumental in the establishment of the 2001 USPTO patentability standards for compliance with the Utility and Written Description requirements of Title 35.

Dr. Stanton received his Ph.D. from the University of Maryland, has published numerous scientific and legal articles and is co-author of a definitive treatise on the Leahy-Smith America Invents Act, “Patents After the AIA: Evolving Law and Practice.” 

Part IV: The Challenges of AI Inventions:  A Moderated Panel Discussion